doi: 56
Studies involving acoustic and chemical insults show that growth factors represent a compelling class of otoprotective compounds (Yagi et al., The HGF mimetic Dihexa is a synthetically derived Angiotensin IV analog that is blood-brain barrier permeable, stable, and orally bioavailable (McCoy et al., in vitro and in vivo , making a strong case for a small molecule activator of HGF/c-Met to confer a neuroprotective benefit (Zhang et al., The experimental value of zebrafish as an animal model for in vivo drug discovery has grown rapidly due to their ease of assessment, large clutch size, and ability to recapitulate human disease conditions (MacRae and Peterson, in vivo , demonstrating that otoprotective drug discovery in zebrafish translates to mammalian systems (Owens et al., In this study, we demonstrate that Dihexa protects lateral line hair cells from aminoglycoside ototoxicity
10.1056/NEJMoa2031054 26 GarlandP.DurnfordA
For instance, the enzyme 5,10- methylenetetrahydrofolate reductase (MeTHFR) is responsible for conversion of folate to its active form (5-methyltetrahydrofolate, 5-MTHF)
People with kidney stones related to high uric acid levels are typically advised to avoid purine-rich foods (UMMC 2013), but a low-animal protein or vegetarian diet that alkalinizes the urine is more important for preventing uric acid stone formation (Kenny 2010
As of September 2023 it is on the FDA's Category 2 list of bulk drug substances that may not be compounded due to significant safety risks, and the agency has scheduled a Pharmacy Compounding Advisory Committee (PCAC) review for July 2026 covering proposed uses in opioid withdrawal, chronic insomnia, and narcolepsy
